
Figure 1: Lurbinectedin swimmer plot of progression-free survival in all individual patients treated with and without primary G-CSF prophylaxis by dose level G-CSF, granulocyte colony-stimulating factor; MTD, maximum tolerated dose; PFS, progression-free survival; PR, partial response; RECIST, Response Evaluation Criteria In Solid Tumors v.1.1 (Japan Clinical Oncology Group translation version); RD, recommended dose.
Tables at a glance
Figures at a glance